Table 1.

Timeline of labs from 1997 until time of presentation in 2024 (mm/dd/yy), including absolute lymphocyte count, CD3, CD19, CD16/56, CD45RO, and mitogen response

​5/19/97 (ERT)6/13/97 (no ERT)3/14/00 (low-dose ERT)9/6/00 (low-dose ERT)12/15/00 (low-dose ERT)6/5/0110/9/024/8/0310/14/031/14/041/6/053/17/054/6/058/25/05 (no ERT)3/15/073/30/07 (no ERT)6/18/07 (no ERT)2/23/24 (no ERT)
ALC (cells/µl) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2.2 1.6 4.3 
CD3+ (cells/µl) ​ 154 ​ 460 ​ 499 319 653 731 365 868 1,325 2,623 1,609 1,819 ​ 1,429 1,500 
CD19+ (cells/µl) ​ ​ ​ 152 ​ 102 50 34 38 30 4 11 86 36 2 ​ 3 25 
CD16+56+ (cells/µl) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3 19 ​ 22 3 ​ 10 101 
CD45RO+ (cells/µl) 93 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 829 436 
Mitogen response ​ ​ Low response to PHA. Low response to PHA. Normal response to PHA. Normal response to PHA. Low response to PHA. Low response to PHA. Low response to PHA. Normal response to PHA. Low response to PHA. Low response to PHA. Low response to PHA. Normal response to PHA. ​ ​ Normal response to conA, PHA, and PWM. ​ 

Some clinical notes were available to verify whether the patient was on ERT, outgrowing his dose of ERT (low-dose ERT), or not on ERT (no ERT). ALC, absolute lymphocyte count. ConA, concanavalin A. PHA, phytohemagglutinin. PWM, poke weed mitogen.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal